The Effect Of Giving Sulvas Ferrrosus In Pregnant Women Of Trimester II - III For Three Weeks Against Hemoglobin And Ferritine Values
The Effect of Giving Ferrostic Sulfas in Pregnant Women in Trimester II-III for Three Weeks Against Hemoglobin and Ferritine Values
Iron deficiency anemia is a serious health problem in Indonesia, especially among pregnant women. According to a survey conducted, the prevalence of anemia has decreased over the years, from 63.5% in 1992 to 50.5% in 1995, and in 1997 it was recorded at 30-40%. This study aims to evaluate the effects of giving ferrostic sulfas in pregnant women in trimester II and III for three weeks, with a focus on changes in hemoglobin and ferritine levels.
Methodology
In this study, 40 pregnant women consisting of 31 people in the second trimester and 9 people in the third trimester were subject to the study. The method used is an experimental design with a longitudinal approach. Before and after giving sulfas ferrocus supplements, hemoglobin and ferritine levels of each subject are measured. Ferrosus sulfas tablets given contain 60 mg of iron, with a dose twice a day for three weeks. Examination of hemoglobin levels is carried out using the cyanhemoglobin formation method with 1700 cell-dyne, while ferritin levels are examined by the ELISA method using IMX Ferritin in the Gleneagle Hospital Laboratory Medan.
Results
The results of the study show that 27 out of 40 pregnant women (67.5%) suffered from anemia, with one of them experiencing severe anemia and the rest experiencing mild anemia. Supplementation with sulfas ferrosus was found to significantly increase hemoglobin levels in pregnant women who experienced anemia (p=0.012; p<0.004). However, there was no significant change in pregnant women who did not suffer from anemia (P>0.5).
On the other hand, in all samples, especially in those with initial ferritine levels less than 12 ng/mL, the administration of sulfas ferrosus caused a significant increase in ferritin levels (p=0.001; p=0.00). Conversely, in subjects with initial ferritine levels ≥ 12 ng/ml, there was no significant increase (p=0.77). This shows that supplementation is more effective in pregnant women who have low iron reserves.
Analysis
Further analysis showed that supplementation with sulfas ferrosus provided a significant increase in ferritin levels in pregnant women who experienced anemia (p=0.002; p<0.001), while in subjects who did not experience anemia, both overall and those with initial ferritin levels less than 12 ng/mL, there was no significant change in ferritin levels after supplementation (p=0.2).
Interestingly, this study also noted that there was no correlation between hemoglobin and ferritine levels, either before (p=0.193) or after (p=0.735) supplementation of ferrostal sulfas. However, fluctuations in hemoglobin levels are always followed by changes in ferritine levels (p=0).
Conclusion
The results of this study indicate the importance of attention to iron supplementation for pregnant women, especially those suffering from anemia. Ferrosus sulfas supplementation is not only able to increase hemoglobin levels, but also ferritine in pregnant women who experience iron deficiency. This confirms the need for health policies to increase awareness and access to iron supplements among pregnant women, in order to reduce the risk of anemia and complications that can endanger the health of the mother and fetus.
Recommendations
Based on the findings of this study, it is recommended that health policies be implemented to increase awareness and access to iron supplements among pregnant women, especially those suffering from anemia. Ferrosus sulfas supplementation should be made available to pregnant women who experience iron deficiency, and healthcare providers should be educated on the importance of iron supplementation in preventing and managing anemia in pregnant women.
Implications
The findings of this study have implications for public health policy and practice. The study highlights the importance of iron supplementation in preventing and managing anemia in pregnant women, and the need for increased awareness and access to iron supplements among pregnant women. The study also underscores the importance of healthcare providers being educated on the importance of iron supplementation in preventing and managing anemia in pregnant women.
Limitations
This study has several limitations. The study was conducted in a small sample size, and the study population was limited to pregnant women in trimester II and III. The study also did not control for other factors that may affect hemoglobin and ferritine levels, such as diet and lifestyle. Future studies should aim to replicate the findings of this study in a larger sample size and with a more diverse population.
Future Directions
Future studies should aim to investigate the effects of ferrostic sulfas supplementation on hemoglobin and ferritine levels in pregnant women in different trimesters. The study should also investigate the effects of ferrostic sulfas supplementation on other outcomes, such as birth weight and maternal mortality. Additionally, future studies should aim to investigate the effects of ferrostic sulfas supplementation on pregnant women with different levels of iron reserves.
Conclusion
In conclusion, this study found that ferrostic sulfas supplementation significantly increased hemoglobin and ferritin levels in pregnant women who experienced anemia. The study also found that supplementation was more effective in pregnant women who had low iron reserves. The findings of this study have implications for public health policy and practice, and highlight the importance of iron supplementation in preventing and managing anemia in pregnant women.
Frequently Asked Questions (FAQs) About Ferrostic Sulfas Supplementation in Pregnant Women
As a follow-up to our previous article on the effects of ferrostic sulfas supplementation in pregnant women, we have compiled a list of frequently asked questions (FAQs) and answers to provide more information and clarity on this important topic.
Q: What is ferrostic sulfas supplementation?
A: Ferrostic sulfas supplementation is a type of iron supplementation that involves taking ferrostic sulfas tablets, which contain 60 mg of iron, twice a day for three weeks. This supplementation is designed to increase hemoglobin and ferritin levels in pregnant women who experience iron deficiency.
Q: Who should take ferrostic sulfas supplementation?
A: Pregnant women who experience iron deficiency, especially those in trimester II and III, should consider taking ferrostic sulfas supplementation. However, it is essential to consult with a healthcare provider before starting any supplementation.
Q: What are the benefits of ferrostic sulfas supplementation?
A: Ferrostic sulfas supplementation has been shown to significantly increase hemoglobin and ferritin levels in pregnant women who experience iron deficiency. This can help prevent and manage anemia, reduce the risk of complications, and promote healthy fetal development.
Q: Can ferrostic sulfas supplementation be taken by pregnant women with normal iron levels?
A: While ferrostic sulfas supplementation is primarily designed for pregnant women with iron deficiency, it is not recommended for pregnant women with normal iron levels. Taking iron supplements when not needed can lead to iron overload, which can cause harm to the mother and fetus.
Q: How long should ferrostic sulfas supplementation be taken?
A: Ferrostic sulfas supplementation should be taken for three weeks, as recommended by the study. However, it is essential to consult with a healthcare provider to determine the best course of treatment for individual needs.
Q: Can ferrostic sulfas supplementation be taken with other medications?
A: It is essential to consult with a healthcare provider before taking ferrostic sulfas supplementation with other medications. Some medications may interact with iron supplements, which can lead to adverse effects.
Q: What are the potential side effects of ferrostic sulfas supplementation?
A: While ferrostic sulfas supplementation is generally well-tolerated, some potential side effects may include nausea, vomiting, diarrhea, and stomach cramps. If these side effects occur, it is essential to consult with a healthcare provider.
Q: Can ferrostic sulfas supplementation be taken during breastfeeding?
A: It is essential to consult with a healthcare provider before taking ferrostic sulfas supplementation during breastfeeding. Iron supplements can pass into breast milk, which may affect the baby's iron levels.
Q: How can I get ferrostic sulfas supplementation?
A: Ferrostic sulfas supplementation is available at most pharmacies and healthcare providers' offices. However, it is essential to consult with a healthcare provider before starting any supplementation.
Q: What are the costs associated with ferrostic sulfas supplementation?
A: The costs associated with ferrostic sulfas supplementation may vary depending on the location and healthcare provider. However, it is generally affordable and covered by most health insurance plans.
Q: Can I take ferrostic sulfas supplementation if I have a history of iron overload?
A: It is essential to consult with a healthcare provider before taking ferrostic sulfas supplementation if you have a history of iron overload. Iron overload can cause harm to the mother and fetus, and taking iron supplements may exacerbate the condition.
Q: Can I take ferrostic sulfas supplementation if I have a history of gastrointestinal problems?
A: It is essential to consult with a healthcare provider before taking ferrostic sulfas supplementation if you have a history of gastrointestinal problems. Iron supplements can exacerbate gastrointestinal issues, such as constipation, diarrhea, and stomach cramps.
Conclusion
In conclusion, ferrostic sulfas supplementation is a safe and effective way to increase hemoglobin and ferritin levels in pregnant women who experience iron deficiency. However, it is essential to consult with a healthcare provider before starting any supplementation to determine the best course of treatment for individual needs.